Baseline FEV1 by period and treatment
| No. | Mean (SD) | |
| FEV1 (l) | ||
| By period | ||
| I2-150 | 51 | 2.42 (0.64) |
| II | 50 | 2.50 (0.68) |
| III | 50 | 2.48 (0.69) |
| By treatment | ||
| IV montelukast | 50 | 2.42 (0.64) |
| Oral montelukast | 51 | 2.48 (0.72) |
| Placebo | 50 | 2.50 (0.64) |
| FEV1(% of predicted) | ||
| By period | ||
| I | 51 | 62.23 (11.97) |
| II | 50 | 64.20 (11.53) |
| III | 50 | 63.94 (12.33) |
| By treatment | ||
| IV montelukast | 50 | 62.28 (11.55) |
| Oral montelukast | 51 | 63.66 (12.82) |
| Placebo | 50 | 64.40 (11.41) |
↵2-150 One patient withdrew after period I (see Results section).